Oncolab
OncoLab is a South Korean preclinical biotech developing ANGel, a hydrogel microparticle drug-delivery platform that reformulates approved oncology antibodies and small molecules into localized, sustained-release combination therapies. It serves global pharma/biotech partners via out-licensing and co-development deals, with lead indication Triple Negative Breast Cancer.
- Company typePrivate
- Founded2024
- HeadquartersCheongju, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Oncolab does
OncoLab Co., Ltd. is a South Korean preclinical biotech founded in May 2024 by CEO Jongseong Kim and CTO Doogie Oh, both with 20+ years of nanogel research experience. The company is developing ANGel, a hydrogel microparticle-based precision formulation and delivery platform designed for peritumoral/perilesional subcutaneous administration in oncology. ANGel integrates localized exposure design, sustained release profile, and modular combination architecture, working with approved antibodies and small-molecule oncology assets to deliver bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level rather than through molecular redesign. The lead program, ANGel-TNBC01/02, targets Triple Negative Breast Cancer and is supported by preclinical data showing >3x improvement in median overall survival versus an approved hyaluronidase comparator; the pipeline additionally includes ANGel-PSC01/02 for prostate cancer and ANGel-Dox01,02 for next-generation antibody/small-molecule co-delivery.
The company operates a B2B partnering-first business model, targeting global pharma and biotech counterparties for platform out-licensing, co-development, and milestone/royalty agreements with multi-layer economics (upfront + development milestones + royalties). Its go-to-market is structured as a data-driven conversion process: technical meeting → PoC design → option/co-development/licensing deal. Headquartered at the Chungbuk Center for Creative Economy and Innovation in Cheongju-si with research operations at the OncoLab Research Institute in Goyang-si, OncoLab holds Korean patent applications filed in 2025, publications in high-impact journals (Nature, PNAS, Nature Communications, JACS, Advanced Healthcare Materials), and has been selected for Korea's Deep Tech TIPS program, the KIPA Chairman's Award (September 2025), and the BIO Europe Startup Spotlight (Top 8, November 2025). Pre-A funding of 1 billion KRW from FuturePlay was secured in November 2025 to advance the platform toward an IND filing targeted for 2026 and global clinical entry.
Oncolab firmographics
Firmographics- Name
- Oncolab
- Legal name
- OncoLab Co., Ltd.
- Website
- https://oncolab.co.kr
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OncoLab is a South Korean preclinical biotech developing ANGel, a hydrogel microparticle drug-delivery platform that reformulates approved oncology antibodies and small molecules into localized, sustained-release combination therapies. It serves global pharma/biotech partners via out-licensing and co-development deals, with lead indication Triple Negative Breast Cancer.
- Ownership category
- akta.pro rank
Oncolab industry classification
Industry- Product category
- Immuno-Oncology Drug Delivery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Oncolab is headquartered
LocationHeadquarters
- HQ city
- Cheongju
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Oncolab business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Out-Licensing: B2B partnering-first model targeting global pharma/biotech companies for platform technology licensing. Multi-layer economics structure including upfront payments, development milestones, and royalties. Designed for programs where approved or clinically validated assets can be upgraded via ANGel formulation.
- Co-Development Agreements: Staged co-development partnerships where preclinical and GLP datasets transition into option/co-development/licensing structures aligned to decision-ready evidence. Includes funded research components where applicable.
- Milestone Payments: Structured deal pathways with option agreements converting to full co-development deals, with development and regulatory milestone payments tied to IND filing, clinical progression, and approval.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Oncolab product offering
Product offeringCore offering
OncoLab develops the ANGel platform, a hydrogel microparticle-based precision formulation and delivery technology designed for peritumoral/perilesional subcutaneous administration. The platform reformulates approved antibodies and small molecule oncology assets into localized, sustained-release combination therapies, expressing bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level without molecular redesign. Its lead clinical validation program targets Triple Negative Breast Cancer (ANGel-TNBC01/02), with additional pipeline programs in prostate cancer and next-generation co-delivery.
Product overview
Oncolab (OncoLaB) is a biotech company developing ANGel, a modular hydrogel microparticle-based drug delivery platform for immuno-oncology. The platform combines antibody surface binding and small molecule payload loading in a single formulation to achieve bispecific-inspired multi-mechanism and ADC-like effects through reformulation of approved antibodies and oncology drugs. The product portfolio includes the core ANGel platform, with lead program ANGel-TNBC01/02 for Triple Negative Breast Cancer, ANGel-PSC01/02 for Prostate Cancer, and ANGel-Dox01,02 for next-generation co-delivery applications.
Differentiator
Problem solved
Functional benefit
Brands
- ANGel: Hydrogel microparticle-based precision formulation and delivery platform for immuno-oncology treatment. Designed for peritumoral/subcutaneous administration, combining antibody surface binding and small molecule payload loading for localized sustained release therapy targeting solid tumors including Triple Negative Breast Cancer.
Products and services
- ANGel Platform Next-generation immuno-oncology drug delivery platform based on hydrogel microparticle precision formulation and delivery for peritumoral/perilesional subcutaneous administration with sustained release. Integrates multi-antibody function (bispecific-inspired multi-mechanism) and payload-driven drug effect (ADC-like action) in a single dosage form by reformulating approved antibodies and small molecule oncology assets without molecular redesign. Licensed or co-developed with global pharma/biotech partners.
- ANGel-TNBC01/02 Lead ANGel clinical validation program for Triple Negative Breast Cancer (TNBC), designed to deliver GLP toxicology, humanized mouse efficacy proof-of-concept, and CMC standardization as a clinical entry proof package for partnering.
- ANGel-PSC01/02 ANGel pipeline program for prostate cancer indication exploration, with initial efficacy exploration and expansion feasibility assessment planned across multiple years.
- ANGel-Dox01,02 Next-generation ANGel pipeline program for co-delivery of multiple therapeutic modalities, including antibody and small molecule payload loading with established release conditions and in vitro validation.
Quantifiable outcome
- >3× improvement in preclinical mOS for TNBC vs approved comparator (~18 months)
- +2 more outcomes
Companies that use Oncolab
Customer profileSegments2 records
Ideal customer profiles1 record
Oncolab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Oncolab partnerships and signals
Strategic signalScale indicators5 records
Recent moves12 records
Expansion highlights6 records
Oncolab competitors and assessment
Company assessmentDirect peers
- Halozyme Therapeutics: Halozyme's ENHANZE platform reformulates approved IV biologics for subcutaneous delivery via a single injected enzyme, generating royalty-bearing licensing deals with Roche, Pfizer, AbbVie, and others — closely analogous to Oncolab's B2B reformulation/licensing motion targeting approved oncology antibodies.
- Cristal Therapeutics: Cristal Therapeutics develops polymeric nanomedicines encapsulating chemotherapy and other payloads for targeted oncology delivery — directly comparable platform-stage nanomedicine company working on localized/targeted oncology therapeutics.
- BIND Therapeutics (acquired by Pfizer): BIND developed Accurins — targeted polymeric nanoparticles for oncology payloads — and was acquired by Pfizer; its platform approach (nanoparticle + payload + targeting) is the closest historical analog to ANGel.
- Nanobiotix: Nanobiotix develops nanoparticle-based therapeutics for solid tumors, including radioenhancers and immune-oncology combinations delivered locally — the closest direct analog to Oncolab's nanoparticle/hydrogel-based local immuno-oncology delivery approach.
- Tarveda Therapeutics: Tarveda develops miniature drug conjugates (nanoparticle-payload conjugates) that combine targeted delivery with payload action in oncology — overlapping with ANGel's antibody+small-molecule payload-in-one-particle concept.
Broad incumbents
- Daiichi Sankyo: Daiichi Sankyo pioneered the ADC modality with Enhertu and Datroway; a primary strategic incumbent whose ADC platforms compete with ANGel's ADC-like payload action and whose antibodies are potential reformulation targets.
- Roche: Roche is the global leader in bispecific antibodies (Hemlibra, Vabysmo, Lunsumio, Columvi) and immuno-oncology combinations — the dominant incumbent whose approved antibodies are potential ANGel reformulation substrates.
- AstraZeneca: AstraZeneca operates in immuno-oncology (Imfinzi) and bispecifics (Datopotamab deruxtecan via partnership) and is one of the most likely pharma partners/licensors for ANGel — and a benchmark for the bispecific/ADC competition.
Emerging players
- Bolt Biotherapeutics: Bolt is a clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates (ISACs) that combine antibody targeting with immune agonism — adjacent to ANGel's bispecific-inspired + payload-action concept at the molecular level.
- Cytovation: Cytovation develops intratumorally administered oncology biologics (CyPepTide platform) — a clinical-stage precedent that validates peritumoral/local administration as a viable oncology delivery strategy analogous to ANGel's SC administration.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Oncolab social profiles
Digital presenceOncolab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncolab leadership team
Management profileNumber of profiles
Profiles9 records
Oncolab funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncolab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncolab
What does Oncolab do?
OncoLab develops the ANGel platform, a hydrogel microparticle-based precision formulation and delivery technology designed for peritumoral/perilesional subcutaneous administration. The platform reformulates approved antibodies and small molecule oncology assets into localized, sustained-release combination therapies, expressing bispecific-inspired multi-mechanism and ADC-like payload action at the formulation level without molecular redesign. Its lead clinical validation program targets Triple Negative Breast Cancer (ANGel-TNBC01/02), with additional pipeline programs in prostate cancer and next-generation co-delivery.
Is Oncolab a public or private company?
Oncolab is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oncolab founded?
Oncolab was founded in 2024. It employs 1 to 10 people.
Where is Oncolab based?
Oncolab is headquartered in Cheongju, South Korea, in the Asia region.
How does Oncolab make money?
Three revenue lines are on record. Platform Out-Licensing is the primary driver. The others are co-Development Agreements and milestone Payments.
Who are Oncolab's main competitors?
Direct peers on record are Halozyme Therapeutics, Cristal Therapeutics, BIND Therapeutics (acquired by Pfizer), Nanobiotix and Tarveda Therapeutics. Broad incumbents are Daiichi Sankyo, Roche and AstraZeneca. Emerging players are Bolt Biotherapeutics and Cytovation.
Does Oncolab have an API?
No public API is recorded for Oncolab.
What industry is Oncolab in?
Oncolab's product category is Immuno-Oncology Drug Delivery Platform. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.